BioLife Solutions director disposes of 13,871 shares

BioLife Solutions director Catherine Coste sold 13,871 shares on October 6, 2026, as part of a merger with Repligen. Under the merger terms, each BioLife share converted to $11.25 in cash and 0.1442 Repligen shares, per the merger agreement.

Original reporting
Published Oct 9, 2026, 1:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BLFS
Bearish
high confidence
Mentioned
$BLFS
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$BLFSBearishLow
01

Why it matters

The insider disposition is the first public report of the director's sale, providing new information for traders.

02

Market read

Primary disclosure of insider sale; modest trading relevance.

03

What to watch

Potential tax planning or diversification needs of the director.

Relevance 4/10Novelty 4/10Timing: post‑merger filing on Oct 6, 2026

Background

BioLife Solutions is completing a merger with Repligen, converting shares into cash and Repligen stock.

Company-level read

Ticker impact

$BLFSBearishHigh confidence
Context

Director Catherine Coste disposed of 13,871 shares in a Form 4 filing related to the merger.

Expected impact

likely downward pressure as market prices in the insider disposition

Evidence & confidence

The filing is a primary disclosure of a director selling a sizable block; such sales often trigger short-term sell pressure.

Market effects

Minimal impact on the broader biotech sector; the news is company‑specific.

Limited to U.S. markets where BLFS trades.

Low global relevance.

Counterpoint

The sale could be a routine liquidity move unrelated to fundamentals.

Key entities

  • BioLife Solutions

    Biotech firm undergoing merger with Repligen.

  • Catherine Coste

    Director of BioLife Solutions who sold shares.

Related articles

$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

$RGENHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.